Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
A Tutusaus, M Stefanovic, L Boix i Ferrero… - Oncotarget, 2018, vol …, 2018 - diposit.ub.edu
Sorafenib, systemic treatment for advanced hepatocellular carcinoma (HCC), and
regorafenib, novel second line treatment after sorafenib failure, have efficacy limited by …
regorafenib, novel second line treatment after sorafenib failure, have efficacy limited by …
Targeting ceramide metabolism in hepatocellular carcinoma: new points for therapeutic intervention
Background: Hepatocellular Carcinoma (HCC) is one of the greatest global health burdens
because of its uncontrolled cell growth and proliferation, aggressive nature as well as …
because of its uncontrolled cell growth and proliferation, aggressive nature as well as …
[HTML][HTML] Inhibition of hepatocellular carcinoma growth by blockade of glycosphingolipid synthesis
R Jennemann, G Federico, D Mathow, M Rabionet… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the most frequent cancers. In vitro studies suggest
that growth and response to therapy of human carcinomas may depend on …
that growth and response to therapy of human carcinomas may depend on …
[HTML][HTML] Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells
SL Abrams, PP Ruvolo, VR Ruvolo, G Ligresti… - Oncotarget, 2017 - ncbi.nlm.nih.gov
A critical problem in leukemia as well as other cancer therapies is the development of
chemotherapeutic drug-resistance. We have developed models of hematopoietic drug …
chemotherapeutic drug-resistance. We have developed models of hematopoietic drug …
[PDF][PDF] Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells
J McCubrey - 2017 - thescholarship.ecu.edu
ABSTRACT A critical problem in leukemia as well as other cancer therapies is the
development of chemotherapeutic drug-resistance. We have developed models of …
development of chemotherapeutic drug-resistance. We have developed models of …